Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JNJ-101556143 in mAPMR Prostate Cancer
NCT07832292Phase 2Recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Sep 2026
- Primary completion
- May 2029
- Countries
- 4
01
Overview
Phase 2, open-label, single-arm trial of JNJ-101556143 in castration-resistant prostate cancer (CRPC), sponsored by Janssen Pharmaceutical. Primary endpoint: Overall Response Rate. Started Sep 2026; status: recruiting.
02
Drugs
JNJ-101556143
03
Conditions
castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on NCT07832292.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07832292.